Login · Contact

Akorn Pharmaceuticals

Akorn Investor Relations
Investor Relations
Webcast ImageWebcast
Akorn, Inc. at Morgan Stanley Global Healthcare Conference (Replay)
09/13/16 at 12:20 p.m. ET
Akorn, Inc. at Morgan Stanley Global Healthcare Conference
Tuesday, September 13, 2016 12:20 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Profile

Akorn, Inc. is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals and branded as well as private-label over-the-counter consumer health products and animal health pharmaceuticals. Akorn is an industry leader in the development, manufacturing and marketing of generic pharmaceutical products in alternate dosage forms. The Company focuses on difficult-to-manufacture sterile and non-sterile dosage forms including, but not limited to, ophthalmics, injectables, oral liquids, otics, topicals, inhalants and nasal sprays.

In order to successfully execute its strategy, Akorn continues to capitalize on its core strengths:

Research and development expertise in alternate dosage forms. The R&D efforts are primarily focused on the development of multisource generic products that are in dosage forms other than oral solid...  More >>

Stock Quote
AKRX (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Change (%) Stock is Up 1.34 (4.81%)
Data as of 09/23/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Notice of Waiver to Holders - 3.50% Convertible Senior Notes due June 1, 2016
Notice of Settlement Method Election - 3.50% Convertible Senior Notes Due 2016
Recent NewsMore >>
08/25/16Akorn Relaunches Ofloxacin Otic Solution
LAKE FOREST, Ill., Aug. 25, 2016 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty pharmaceutical company, today announced that it has relaunched Ofloxacin Otic Solution 0.3%, a sterile aqueous anti-infective solution for otic use. About Ofloxacin Otic Solution Ofloxacin Otic Solution is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below: Otitis Externa in adults and pediat... 
Printer Friendly Version
08/24/16Akorn to Present at Morgan Stanley Global Healthcare Conference
LAKE FOREST, Ill., Aug. 24, 2016 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today announced that Akorn’s CEO, Raj Rai, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference. Event: Morgan Stanley Healthcare Conference Date: September 13, 2016 Time: 12:20 p.m. ET Location: New York, NY The fireside chat will be webcast live and available on the “Events & Presentations” page in the Investor Relati... 
Printer Friendly Version
08/18/16Akorn Appoints Robert Monahan as Senior Vice President of Corporate Development
LAKE FOREST, Ill., Aug. 18, 2016 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today announced that Rob Monahan has recently joined Akorn as Senior Vice President of Corporate Development. Mr. Monahan joins Akorn from Walgreens Boots Alliance, Inc. (formerly Walgreen Co.), where he was a corporate development professional focused on Mergers & Acquisitions since 2009, most recently as Vice President of Mergers & Acquisitions.  At W... 
Printer Friendly Version
Latest Investor PresentationMore >>
09/09/16September 2016 Investor Presentation Download Documentation 
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Akorn, Inc. posts new information to the site. Just enter your e-mail address and click Submit.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.